Here are four highlights:
1. Operating expenses for the third quarter were $2.1 million, compared to $6.3 million in the third quarter of 2017.
2. InVivo anticipates it will continue to maintain its current cash burn rate of less than $1 million per month, including expenses related to clinical studies.
3. The company reported a $3.2 million net loss for the quarter, compared to the $9.4 million net loss in the third quarter of 2017.
4. InVivo ended the quarter with $19.7 million of cash and cash equivalents.
To view the full financial report, click here.
More articles on biologics:
Imagion Biosystems incorporates ‘printer & ink’ business model for medical imaging
SpinalCyte receives additional patents: 3 takeaways
3 things to know about Lattice Biologics’ CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
